Results 181 to 190 of about 552,206 (313)

Repurposing α-Blockers Alfuzosin and Doxazosin for Cancer Therapy: Integrated Experimental, Mechanistic, and Molecular Docking Studies. [PDF]

Pharmaceuticals (Basel)
Alanazi MM.
europepmc   +1 more source

Concerted Action of Targeted Nucleic Acid Therapeutics as Flexible, Precision and Personalized Cancer Treatment

Advanced Science, EarlyView.
Combinations of small activating RNAs and small interfering RNAs were developed as personalized precision therapies that simultaneously activate tumor suppressors and silence oncogenes according to the molecular signatures of patient tumors. This combination strategy demonstrated superior anticancer efficacy, highlighting the promise of precision ...
Jing Wu, Jiaxuan Chen, Abdechakour Elkihel, Wenjun Lan, Nicolas Fraunhoffer, Dandan Zhu, Baoping Lian, Christina Galanakou, Zhancun Bian, Xi Liu, Odile Gayet, Loic Moubri, Julie Aglietti Roques, Vikash Reebye, Nagy Habib, Xiaoxuan Liu, Nelson Dusetti, Juan Lucio Iovanna, Ling Peng   +18 more
wiley   +1 more source

Factors associated with treatment resumption and long-term outcomes after ICU discharge in patients with hematological malignancies. [PDF]

Ann Intensive Care
Messéant O, Guégan M, Painvin B, Maamar A, Mear JB, Reignier J, Canet E, Tadié JM, Benguerfi S.   +8 more
europepmc   +1 more source

Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy

Advanced Science, EarlyView.
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier, Megane Grah Kple, Julen Ariztia, Marion Leroux, Mathieu Moreau, Michael Claron, Maxime Cheveau, Adam Laouafa, Agnieszka Kownacka, Camille Petitot, John Simonet, Alexandre M. M. Dias, Sophie Poty, Charles Truillet, Bertrand Collin, Alexandra Oudot, Franck Denat   +16 more
wiley   +1 more source

Retraction: Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models. [PDF]

Front Oncol
Frontiers Editorial Office.
europepmc   +1 more source

Artificial Intelligence‐Guided Phenotypic Drug Repurposing Against Streptococcus pneumoniae

Advanced Science, EarlyView.
Integrated artificial intelligence (AI) ensembles identify highly potent repurposed drugs against Streptococcus pneumoniae. Prospective virtual screening of 6747 drugs uncovers nine active candidates, including thiostrepton. This drug exhibits low picomolar potency and bypasses established resistance in multidrug‐resistant strains, demonstrating an ...
Joshua S. Fitch, Muhammad D. Ariadi, Min Jung Kwun, Leonie Howells, Saiveth Hernandez‐Hernandez, Nicholas J. Croucher, Pedro J. Ballester   +6 more
wiley   +1 more source

Nicotinonitriles-based therapeutics as versatile pharmacophores in rational anticancer drug design. [PDF]

RSC Adv
Nafie MS, Zeidan MA, Fahmy SA, Diab MK, Darwish KM, Yassen ASA.   +5 more
europepmc   +1 more source

Modification‐Selective Inhibition of Succinate Dehydrogenase a Enables Tumor‐Restricted Mitochondrial Modulation

Advanced Science, EarlyView.
This work identifies acetylation‐dependent SDHA homeostasis as a determinant of tumor‐specific metabolic vulnerability. Guided by this mechanism, a modification‐selective inhibitor, ZPI‐3, selectively targets non‐acetylated SDHA, achieving tumor‐restricted SDH inhibition and effective bladder cancer control. Differential responses in clinical specimens
Kaikai Xu, Lulu Kong, Kebin Ye, Xinlu Bao, Haowen Liu, Ning Wang, Yongming Deng, Wei Wang, Shaohua Wei, Lin Zhou   +9 more
wiley   +1 more source

Impact of intensive care unit admission on the resumption of treatment in patients with cancer: a systematic review and meta-analysis. [PDF]

Support Care Cancer
do Val Roso R, Daltro-Oliveira R, Munshi L, Nassar Junior AP.   +3 more
europepmc   +1 more source

Blood Cell‐Camouflaged Liquid Metal Nanoconjugates Orchestrate Treg Depletion and STING‐Amplified Photothermal Immunity for Metastatic Triple‐Negative Breast Cancer Therapy

Advanced Science, EarlyView.
Whole‐blood biomimetic engineering transforms liquid metal nanoparticles into a tripartite immunotherapeutic platform that orchestrates regulatory T‐cell depletion, photothermal‐induced immunogenic cell death, and activation of the stimulator of interferon genes pathway.
Nina Sang, Eijiro Miyako
wiley   +1 more source